Loss in Life Expectancy after Surgical Aortic Valve Replacement

This study found after surgical aortic valve replacement (SAVR) patients had shorter life expectancy, compared against the general population. This loss in life expectancy was significant, especially in young patients. These results provide essential information to advice patients before and after SAVR.

Remodelado miocárdico reverso luego del reemplazo valvular

This is an observational national cohort study to assess long term relative survival and estimated loss in life expectancy after SAVR.

The study included 23528 patients undergoing SAVR with or without concomitant myocardial revascularization surgery in Sweden between 1995 and 2013 from the registry SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies). Life expectancy of the Swedish general population was estimated and matched by sex, age and year of surgery.

Over 19 years, researchers observed 21%, with and expected survival of 34%, and 63% relative survival. Loss in life expectancy was 1.9 years for the study population but varied with age. ≥80 patients only lost 0.4 years vs. 4.4 in <50 year olds.


Read also: Clinical Implications of the New Hypertension Guidelines.


There were no differences between men and women.

Conclusion

Patients undergoing surgical aortic valve replacement lose life expectancy compared against the general population, significantly, and especially the younger patients. This information is relevant to better advice our patients before and after SAVR.

Original Title: Loss in Life Expectancy After Surgical Aortic Valve Replacement. SWEDEHEART Study.

Reference: Natalie Glaser et al. J Am Coll Cardiol 2019;74:26–33.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...